BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

Core Insights - BioRestorative Therapies, Inc. is a clinical stage regenerative medicine company focused on stem cell-based therapies and products [1] - The CEO, Lance Alstodt, will be interviewed during the Benzinga All-Access Show on June 18, 2025 [1][2] Company Overview - BioRestorative develops therapeutic products using adult stem cells, with two main clinical development programs targeting disc/spine disease and metabolic disorders [3] - The company also operates a commercial BioCosmeceutical platform [5] Clinical Development Programs - Disc/Spine Program (brtxDISC): The lead candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells from the patient's bone marrow, aimed at treating painful lumbosacral disc disorders and is currently in Phase 2 clinical trials for chronic lower back pain [3] - Metabolic Program (ThermoStem): This program focuses on using brown adipose-derived stem cells to target obesity and metabolic disorders, with preclinical research indicating potential benefits in caloric burning and reduced glucose and lipid levels [4] Commercial BioCosmeceuticals - The company has a commercial BioCosmeceutical product that is a cell-based secretome designed to reduce fine lines and wrinkles, with plans to expand its offerings in the aesthetic products and therapeutics space [5]